STENOCARE – Innovative New ASTRUM Product Officially Approved for Sale in Norway
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
STENOCARE A/S (“Stenocare” or the "Company") is proud to announce the approval of its innovative product, Astrum 10-10, for sale in Norway. This milestone paves the way for more patients to access the benefits of medical cannabis treatment. Astrum 10-10 is expected to become available to patients within the next 30 days.
Since 2019, Stenocare has been collaborating with partners to develop and test next-generation medical cannabis oil products, positioning itself as a frontrunner in prescription-based medical cannabis. Stenocare is now ready to introduce its patented product to Norwegian patients. Officially named “Astrum 10-10 Oil Stenocare,” the product contains 10 mg/ml THC and 10 mg/ml CBD in a 30 ml bottle.
Innovative Product: The Stenocare Astrum product is based on cutting-edge oil technology designed to enhance the bioavailability of cannabinoids in the patient’s bloodstream. This innovation addresses a well-known challenge in medicine dosing by ensuring consistent uptake of active ingredients into the blood. With the Astrum product, Stenocare has successfully completed a pharmacokinetic (PK) study in dogs, documenting two critical parameters in the lymphatic system that can significantly improve bioavailability:
Parameter 1 – Uptake in the Blood: According to the pharmacokinetic (PK) study in dogs, Astrum improves blood uptake by a factor of 2.6 compared to a reference MCT-oil product on the market. Low and inconsistent uptake of drugs in the blood across patients is a well-known challenge in the pharmaceutical industry, affecting most medications. This challenge also applies to medical cannabis. When patients use traditional MCT-oil-based medical cannabis, the metabolism often reduces the uptake of cannabinoids in the body. As a result, a highly variable and often limited amount of active ingredients (i.e., cannabinoids) reaches the patient with a therapeutic effect. This creates difficulties in prescribing a consistent dosage to patients. Additionally, blood uptake varies significantly from one individual to another due to biological differences. The new Astrum product helps mitigate these challenges by offering enhanced bioavailability.
Parameter 2 – Time to Maximum Effect: According to the pharmacokinetic (PK) study in dogs, the Stenocare Astrum product reduces the time from dosing to maximum effect from 2-4 hours to just 1 hour, providing a more consistent experience for patients. Predictability of uptake and time to maximum effect is crucial when doctors prescribe medical cannabis and when patients use it to treat their symptoms. Time to maximum effect refers to the duration it takes for the medication to reach its highest concentration in the blood after administration. Achieving this maximum effect as quickly as possible is important to help patients manage their symptoms effectively.
CEO of Stenocare, Thomas Skovlund Schnegelsberg, comments: "Our Astrum 10-10 oil was initially approved for sale in Australia and Germany, and we are now proud to add Norway to the list. We believe the new Astrum product represents a groundbreaking advancement for the entire medical cannabis industry and Norwegian patients alike. This innovative product directly addresses key challenges with bioavailability in patients, supported by robust data from a pharmacokinetic study in dogs that validates its benefits. With this milestone, Stenocare is firmly positioned as a first-mover in the next generation of medical cannabis oil products, poised to revolutionise the market."
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com
About STENOCARE A/S
STENOCARE A/S, founded in 2017, supplies prescription-based medical cannabis to patients in Denmark and internationally. It was the first company to receive permission from the Danish Medicines Agency to import, distribute, cultivate, and produce medical cannabis. Today, STENOCARE sources its products from a selection of high-quality international suppliers that comply with the strict European Good Manufacturing Practices (EU-GMP). STENOCARE has developed a unique patented medical cannabis oil product, ASTRUM, which provides improved bioavailability of active ingredients for patients. The company has strategically invested in assets to operate within the highly regulated pharmaceutical industry, with products approved for sale in multiple countries.
www.stenocare.com www.stenocare.dk www.stenocare.se